George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage…
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – –…
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Phase III trial informed by comprehensive KARDIA data set generated through three…
